uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.
Key claim: A uPAR-targeting GFD-CD3 bispecific T-cell engager eliminates senescent cells and alleviates age-related pathologies in aged mice and non-human primates when low doses are guided by serum aminotransferase monitoring, offering a more dose-titratable alternative to senolytic CAR-T cells.
Abstract
Senolytic CAR-T cells targeting uPAR induce dose-dependent toxicities. Although dosage adjustment mitigates these toxicities in laboratory mice, clinical translation remains challenging owing to the unpredictability of CAR-T cell proliferation across heterogeneous patient populations. In contrast, bispecific T-cell engagers (BiTEs) offer a safer alternative with superior dose-titratability. Here, we have developed a GFD-CD3 BiTE by employing the growth factor-like domain (GFD) of the natural ligand uPA as the targeting moiety to target uPAR-positive senescent cells. Dose-range finding studies revealed that high-dose GFD-CD3 predominantly induced hepatotoxicity through T cell-mediated attack on hepatic endothelial cells. Crucially, under transaminase-guided monitoring, low-dose GFD-CD3 effectively eliminated senescent cells and alleviated age-related pathologies in aged mice and non-human primates without adverse effects. These findings establish GFD-CD3 as a clinically translatable senolytic agent and provide the compelling preclinical evidence for BiTE as a senolytic strategy.
Why this matters
Senolytic development has leaned on either small molecules (dasatinib+quercetin, fisetin) or living cell therapies (CAR-T), each with distinct problems — poor specificity on one end, undosable persistence on the other. A bispecific T-cell engager hitting the same uPAR antigen as senolytic CAR-T, but with a serum-aminotransferase safety dial and non-human primate data, is the first preclinical signal that T-cell-redirected senolysis might be delivered as a titratable drug rather than a one-shot cell product. The trend story to track is whether this reframes ‘senolytic immunotherapy’ away from CAR-T toward off-the-shelf biologics before any human aging data exist.